Recent studies have demonstrated that certain RASGRF1 fusion are oncogenic drivers in NSCLC that primarily affect the MAPK and PI3K signaling pathways; these include the TMEM87A-RASGRF1 fusion and OCLN-RASGRF1 fusion (Cooper et al., 2020; Hunihan et al., 2022). The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.